Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: MiNK Therapeutics Inc., 3 years.
MiNK Therapeutics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
MiNK Therapeutics Inc. June 12, 202498.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | MiNK Therapeutics Inc. | Grant or award | +1,485 | $10.95 | $16,261 |
| Jun 1, 2026 | MiNK Therapeutics Inc. | Grant or award | +1,313 | $12.38 | $16,255 |
| Mar 2, 2026 | MiNK Therapeutics Inc. | Grant or award | +1,491 | $10.90 | $16,252 |
| Dec 1, 2025 | MiNK Therapeutics Inc. | Grant or award | +1,466 | $11.09 | $16,258 |
| Sep 2, 2025 | MiNK Therapeutics Inc. | Grant or award | +1,173 | $13.86 | $16,258 |
| Jun 2, 2025 | MiNK Therapeutics Inc. | Grant or award | +2,267 | $7.17 | $16,254 |
| Mar 3, 2025 | MiNK Therapeutics Inc. | Grant or award | +1,849 | $8.79 | $16,253 |
| Dec 1, 2024 | MiNK Therapeutics Inc. | Grant or award | +20,987 | $0.73 | $15,321 |
| Sep 3, 2024 | MiNK Therapeutics Inc. | Grant or award | +18,753 | $0.82 | $15,377 |
| Jun 3, 2024 | MiNK Therapeutics Inc. | Grant or award | +15,454 | $0.99 | $15,299 |
| Mar 1, 2024 | MiNK Therapeutics Inc. | Grant or award | +16,185 | $0.95 | $15,376 |
| Dec 1, 2023 | MiNK Therapeutics Inc. | Grant or award | +14,784 | $1.04 | $15,375 |
| Sep 1, 2023 | MiNK Therapeutics Inc. | Grant or award | +10,531 | $1.46 | $15,375 |
| Jun 1, 2023 | MiNK Therapeutics Inc. | Grant or award | +8,736 | $1.76 | $15,375 |
| Mar 1, 2023 | MiNK Therapeutics Inc. | Grant or award | +7,357 | $2.09 | $15,376 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.